Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,592 Shares of Stock

Key Points

• Oluyemi Okupe, CFO of Hims & Hers Health, sold 11,592 shares at an average price of $57.13, resulting in a total transaction value of approximately $662,250.96 and a 14.17% decrease in his holdings.
• Despite the recent insider sales, Hims & Hers Health's stock increased by 3.3%, closing at $51.40 with a market cap of $11.62 billion.
• Analysts have issued mixed ratings on Hims & Hers Health, with the stock receiving two "Buy," nine "Hold," and three "Sell" ratings, along with an average price target of $38.92.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,592 shares of the firm's stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96. Following the sale, the chief financial officer directly owned 70,232 shares of the company's stock, valued at approximately $4,012,354.16. The trade was a 14.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.72, for a total value of $669,263.40.
• On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.20, for a total transaction of $5,117,000.00.
• On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.74, for a total transaction of $1,361,740.16.
• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89.

Hims & Hers Health Stock Up 3.3%

Shares of NYSE:HIMS traded up $1.62 during trading on Monday, hitting $51.40. 29,974,475 shares of the company's stock traded hands, compared to its average volume of 32,895,539. The company has a market cap of $11.62 billion, a price-to-earnings ratio of 64.25, a price-to-earnings-growth ratio of 3.39 and a beta of 2.25. The company has a 50-day moving average price of $51.01 and a 200-day moving average price of $49.03. Hims & Hers Health, Inc. has a 52 week low of $18.33 and a 52 week high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the business posted $0.06 EPS. The firm's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on HIMS shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Canaccord Genuity Group reiterated a "buy" rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Reduce" and an average price target of $38.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Goldstone Financial Group LLC bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at approximately $653,000. Carnegie Investment Counsel increased its holdings in shares of Hims & Hers Health by 25.4% during the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company's stock worth $17,238,000 after buying an additional 61,560 shares in the last quarter. CWM LLC lifted its stake in shares of Hims & Hers Health by 8.0% in the 3rd quarter. CWM LLC now owns 9,749 shares of the company's stock valued at $553,000 after acquiring an additional 725 shares during the last quarter. Pacer Advisors Inc. grew its position in Hims & Hers Health by 193.8% during the 3rd quarter. Pacer Advisors Inc. now owns 27,260 shares of the company's stock worth $1,546,000 after acquiring an additional 17,980 shares during the last quarter. Finally, Cadent Capital Advisors LLC acquired a new position in Hims & Hers Health in the 3rd quarter worth about $1,603,000. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.